CONMED Corporation
CNMD
$59.12
-$2.81-4.54%
| Weiss Ratings | CNMD - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | C | |||
| Rating Factors | CNMD - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Weak | |||
| Growth Index | Excellent | |||
| Efficiency Index | Good | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | CNMD - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.52 | |||
| Price History | CNMD - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 1.35% | |||
| 30-Day Total Return | -16.70% | |||
| 60-Day Total Return | -19.13% | |||
| 90-Day Total Return | -8.33% | |||
| Year to Date Total Return | -12.22% | |||
| 1-Year Total Return | -29.67% | |||
| 2-Year Total Return | -33.37% | |||
| 3-Year Total Return | -55.47% | |||
| 5-Year Total Return | -8.80% | |||
| 52-Week High % Change | -28.78% | |||
| 52-Week Low % Change | 12.15% | |||
| Price | CNMD - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $86.96 | |||
| 52-Week Low Price | $55.22 | |||
| 52-Week Low Price (Date) | Mar 04, 2025 | |||
| 52-Week High Price (Date) | Mar 13, 2024 | |||
| Valuation | CNMD - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.91B | |||
| Enterprise Value | 2.84B | |||
| Price/Earnings (TTM) | 14.61 | |||
| Earnings Per Share (TTM) | 4.24 | |||
| Earnings Per Share Growth | 107.80% | |||
| Price/Earnings To Growth | 0.14 | |||
| Price/Sales (TTM) | 1.48 | |||
| Price/Book (Q) | 1.99 | |||
| Enterprise Value/Revenue (TTM) | 2.17 | |||
| Price | $59.12 | |||
| Enterprise Value/EBITDA (TTM) | 12.26 | |||
| Enterprise Value/EBIT | 17.63 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | CNMD - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 31.15M | |||
| Dividend Yield | 1.29% | |||
| Div. Per Share (Most Recent) | $0.20 | |||
| Dividend Per Share (TTM) | $0.80 | |||
| Payout Ratio (TTM) | 18.62% | |||
| Dividend Per Share (Most Recent) | $0.20 | |||
| Company Info | CNMD - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 727 392 6464 | |||
| Address | 11311 Concept Boulevard Largo, FL 33773-4908 | |||
| Website | www.conmed.com | |||
| Country | United States | |||
| Year Founded | 1970 | |||
| Profitability | CNMD - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 12.31% | |||
| Profit Margin | 10.13% | |||
| Management Effectiveness | CNMD - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 4.37% | |||
| Return on Equity | 14.74% | |||
| Income Statement | CNMD - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 1.31B | |||
| Total Revenue (TTM) | 1.31B | |||
| Revenue Per Share | $41.96 | |||
| Gross Profit (TTM) | 734.63M | |||
| EBITDA (TTM) | 231.39M | |||
| EBIT (TTM) | 160.93M | |||
| Net Income (TTM) | 132.42M | |||
| Net Income Avl. to Common (TTM) | 132.42M | |||
| Total Revenue Growth (Q YOY) | 5.78% | |||
| Earnings Growth (Q YOY) | 2.07% | |||
| EPS Diluted (TTM) | 4.24 | |||
| EPS Diluted Growth (Q YOY) | 2.79% | |||
| Balance Sheet | CNMD - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 24.46M | |||
| Cash Per Share (Q) | $0.79 | |||
| Total Current Assets (Q) | 640.01M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 962.68M | |||
| Current Ratio (Q) | 2.301 | |||
| Book Value Per Share (Q) | $31.15 | |||
| Total Assets (Q) | 2.31B | |||
| Total Current Liabilities (Q) | 278.13M | |||
| Total Debt (Q) | 947.16M | |||
| Total Liabilities (Q) | 1.34B | |||
| Total Common Equity (Q) | 962.68M | |||
| Cash Flow | CNMD - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -13.08M | |||
| Cash from Financing (TTM) | -151.00M | |||
| Net Change in Cash (TTM) | 163.00K | |||
| Levered Free Cash Flow (TTM) | 96.82M | |||
| Cash from Operations (TTM) | 166.97M | |||
